Genotyping of CYP2C9 for cardiovascular patients / Norshazareen Abd Manab

CYP2C9 lines the important drug-metabolizing cytochrome P450 isoforms in the human liver but linked with inter-individual variation in drug-response relationship due to single nucleotide polymorphism of the encoding gene. Modification of CYP2C9 activity due to genetic factor alters the metabolism of...

Full description

Saved in:

Bibliographic Details
Main Author:	Abd Manab, Norshazareen
Format:	Thesis
Language:	English
Published:	2005
Subjects:	RM Therapeutics Pharmacology RS Pharmacy and materia medica
Online Access:	https://ir.uitm.edu.my/id/eprint/98633/1/98633.PDF
Tags:	Add Tag No Tags, Be the first to tag this record!

id	my-uitm-ir.98633
record_format	uketd_dc
spelling	my-uitm-ir.986332024-07-22T08:15:14Z Genotyping of CYP2C9 for cardiovascular patients / Norshazareen Abd Manab 2005 Abd Manab, Norshazareen RM Therapeutics. Pharmacology RS Pharmacy and materia medica CYP2C9 lines the important drug-metabolizing cytochrome P450 isoforms in the human liver but linked with inter-individual variation in drug-response relationship due to single nucleotide polymorphism of the encoding gene. Modification of CYP2C9 activity due to genetic factor alters the metabolism of drug substrates resulting in reduced efficacy or worse, toxicity. Amongst substrates of CYP2C9, warfarin is of special interest due to its narrow therapeutic index. The objective of this study is to determine the type and frequency of CYP2C9 polymorphism among patients on warfarin therapy. We successfully genotyped 180 patients who were on warfarin from 183 samples. The genomic DNA was obtained from the gene pool of Universiti Teknologi Mara Pharmacogenomic Research Group.The DNA was genotyped for known CYP2C9 polymorphic allelic (CYP2C92, 3 and 7) variants with the use of allele specific multiplex polymerase chain reaction and the product was resolved via gel electrophoresis. Polymorphic variants of CYP2C9 (CYP2C92 and CYP2C94) were not detected in these patients. Among the 180 patients, the genotype frequency of CYP2C91/1 was 92.7% and CYP2C9l/3 was 7.3%. There was only two genotype expressed in patients on warfarin therapy, CYP2C91/1 and CYP2C9l/*3. This provide a useful database to help physician predict the possibility of adverse drug reaction among patients on warfarin in Malaysia. 2005 Thesis https://ir.uitm.edu.my/id/eprint/98633/ https://ir.uitm.edu.my/id/eprint/98633/1/98633.PDF text en public degree Universiti Teknologi MARA (Kampus Puncak Alam) Faculty of Pharmacy Kek, Teh Lay
institution	Universiti Teknologi MARA
collection	UiTM Institutional Repository
language	English
advisor	Kek, Teh Lay
topic	RM Therapeutics Pharmacology RS Pharmacy and materia medica
spellingShingle	RM Therapeutics Pharmacology RS Pharmacy and materia medica Abd Manab, Norshazareen Genotyping of CYP2C9 for cardiovascular patients / Norshazareen Abd Manab
description	CYP2C9 lines the important drug-metabolizing cytochrome P450 isoforms in the human liver but linked with inter-individual variation in drug-response relationship due to single nucleotide polymorphism of the encoding gene. Modification of CYP2C9 activity due to genetic factor alters the metabolism of drug substrates resulting in reduced efficacy or worse, toxicity. Amongst substrates of CYP2C9, warfarin is of special interest due to its narrow therapeutic index. The objective of this study is to determine the type and frequency of CYP2C9 polymorphism among patients on warfarin therapy. We successfully genotyped 180 patients who were on warfarin from 183 samples. The genomic DNA was obtained from the gene pool of Universiti Teknologi Mara Pharmacogenomic Research Group.The DNA was genotyped for known CYP2C9 polymorphic allelic (CYP2C92, 3 and 7) variants with the use of allele specific multiplex polymerase chain reaction and the product was resolved via gel electrophoresis. Polymorphic variants of CYP2C9 (CYP2C92 and CYP2C94) were not detected in these patients. Among the 180 patients, the genotype frequency of CYP2C91/1 was 92.7% and CYP2C9l/3 was 7.3%. There was only two genotype expressed in patients on warfarin therapy, CYP2C91/1 and CYP2C9l/*3. This provide a useful database to help physician predict the possibility of adverse drug reaction among patients on warfarin in Malaysia.
format	Thesis
qualification_level	Bachelor degree
author	Abd Manab, Norshazareen
author_facet	Abd Manab, Norshazareen
author_sort	Abd Manab, Norshazareen
title	Genotyping of CYP2C9 for cardiovascular patients / Norshazareen Abd Manab
title_short	Genotyping of CYP2C9 for cardiovascular patients / Norshazareen Abd Manab
title_full	Genotyping of CYP2C9 for cardiovascular patients / Norshazareen Abd Manab
title_fullStr	Genotyping of CYP2C9 for cardiovascular patients / Norshazareen Abd Manab
title_full_unstemmed	Genotyping of CYP2C9 for cardiovascular patients / Norshazareen Abd Manab
title_sort	genotyping of cyp2c9 for cardiovascular patients / norshazareen abd manab
granting_institution	Universiti Teknologi MARA (Kampus Puncak Alam)
granting_department	Faculty of Pharmacy
publishDate	2005
url	https://ir.uitm.edu.my/id/eprint/98633/1/98633.PDF
_version_	1811768947639320576

Genotyping of CYP2C9 for cardiovascular patients / Norshazareen Abd Manab

Similar Items